Výsledky vyhledávání

(396) Effects of Long-term Testosterone Therapy in Men with Functional Hypogonadism and Obesity on Weight, Waist Circumference, and Erectile Function – Results from a Registry Study

Autor: F Saad, K S Haider, A Haider, G Doros, A Traish

Publikováno v: The Journal of Sexual Medicine. 20

Introduction Obesity is a risk factor for erectile dysfunction (ED). Long-term testosterone therapy (TTh) has been shown to improve anthropometric parameters as well as erectile function. Objective to investigate effects of long-term TTh up to 13 yea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::40feac07f19d4b49779612f10c02211c
https://doi.org/10.1093/jsxmed/qdad060.370

Zobrazit plný text záznamu

(076) Effects of Long-term Testosterone Therapy on Erectile Function, Sexual Activity, and Quality of Life in Hypogonadal Men with Type 2 Diabetes – Results from a Registry Study

Autor: A Haider, K S Haider, G Doros, A Traish, F Saad

Publikováno v: The Journal of Sexual Medicine. 20

Introduction Treatment of erectile function (EF) in men with type 2 diabetes (T2DM) remains challenging. EF and sexual activity contribute to quality of life (QoL) in aging men. Objective to investigate effects of long-term TTh up to 13 years in men

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0eb2d0b60589951bbc5b0bf6684c182e
https://doi.org/10.1093/jsxmed/qdad060.072

Zobrazit plný text záznamu

(398) Remission of Type 2 Diabetes, Mortality, and Major Adverse Cardiovascular Events in Men with Hypogonadism and Type 2 Diabetes Receiving Long-term Testosterone Therapy in Comparison to an Untreated Control Group in a Urological Registry Study

Autor: K S Haider, A Haider, G Doros, A Traish, F Saad

Publikováno v: The Journal of Sexual Medicine. 20

Introduction We had reported previously that 34.3% of patients with hypogonadism and type 2 diabetes (T2DM) receiving testosterone therapy (TTh) up to 11 years in our registry study achieved remission of their T2DM after a mean time of 8.6±2.9 years

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4b99400c9e34b8066f14ce4f99d0900a
https://doi.org/10.1093/jsxmed/qdad060.372

Zobrazit plný text záznamu

(496) Effects of Long-term Testosterone Therapy in Men with Functional Hypogonadism and Obesity on the Lipid Pattern – Results from a Registry Study

Autor: A Haider, K S Haider, G Doros, A Traish, F Saad

Publikováno v: The Journal of Sexual Medicine. 20

Introduction The lipid pattern plays a role in the assessment of cardiometabolic risks such as atherogenicity (non-HDL), arteriosclerotic cardiovascular disease (remnant cholesterol), or insulin resistance (TG:HDL ratio). A recent meta-analysis sugge

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::02ef3215b54e9fb84df9a7244bee2003
https://doi.org/10.1093/jsxmed/qdad060.468

Zobrazit plný text záznamu

(071) Effects of Long-term Testosterone Therapy on Erectile Function, Sexual Activity, and Quality of Life in Men with Functional Hypogonadism – results from a registry study

Autor: K S Haider, A Haider, G Doros, A Traish, F Saad

Publikováno v: The Journal of Sexual Medicine. 20

Introduction Erectile function (EF) and sexual activity contribute to quality of life (QoL) in aging men. Testosterone therapy (TTh) has well-established beneficial effects on EF and QoL while there is less information on sexual activity. Objective t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e84dc8e42620eda1a9dc71cdcb13e9ca
https://doi.org/10.1093/jsxmed/qdad060.067

Zobrazit plný text záznamu

(397) Long-term Testosterone Therapy in Men with Functional Hypogonadism and Obesity Improves Surrogate Parameters of Liver Function in a Urological Registry Study

Autor: F Saad, K S Haider, A Haider, G Doros, A Traish

Publikováno v: The Journal of Sexual Medicine. 20

Introduction Hepatic steatosis is highly prevalent in patients with hypogonadism and obesity. Fatty liver is increasingly recognized as cardiovascular risk factor. The gold standard assessment – histological evaluation of liver biopsies – cannot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::81eddf083d93a9f27a1b5fdfeb5d14d2
https://doi.org/10.1093/jsxmed/qdad060.371

Zobrazit plný text záznamu

Einflussfaktoren bei der Wahl der Androgendeprivationstherapie für Patienten mit hormonsensitiven Prostatakarzinom

Autor: S. Baumann, A. Haider, M. Flesch, Jan Lehmann, M. Gedamke, C. W. Kluike, K. S Haider, D. Kägebein

Publikováno v: Der Urologe. 61:173-182

Zusammenfassung Hintergrund Die Androgendeprivationstherapie (ADT) mit einem GnRH-Agonisten (Gonadotropin-releasing-Hormon) oder -Antagonisten stellt einen zentralen Bestandteil der Behandlung des Prostatakarzinoms (PCa) dar. Über die Faktoren, welc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ca5bebbe27308e806482c3fa526b1c50
https://doi.org/10.1007/s00120-021-01620-7

Zobrazit plný text záznamu

[Factors influencing the choice of androgen deprivation therapy for patients with hormone-sensitive prostate cancer : Results of the ProComD study]

Autor: J, Lehmann, C W, Kluike, A, Haider, K S, Haider, S, Baumann, M, Flesch, M, Gedamke, D, Kägebein

Publikováno v: Der Urologe. Ausg. ALiteratur. 61(2)

Androgen deprivation therapy (ADT) with a GnRH agonist or the GnRH antagonist degarelix is a central component in the treatment of prostate cancer (PCa). Little is currently known regarding the decision criteria. Knowledge of these could improve the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1f150f08dac7eb10dd9e57b0619b3abf
https://pubmed.ncbi.nlm.nih.gov/34402941

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání